GeneDx Q2 Revenue Beats, Swings to Profit, Reaffirms Guidance
WGS sits 87% above its 52-week low of $32.21.
Summary
GeneDx delivered a strong Q2: revenue of $114.4M beat the $111M consensus, and the company swung to a small adjusted net profit of $0.4M from a loss last quarter. Exome and genome test volume jumped 32% year-over-year, driving the beat. Management reaffirmed full-year revenue guidance of $475M-$490M and set Q3 guidance at $122M-$124M, signaling confidence in sustained growth. This follows a series of heavy insider buying in May and June, with directors and 10% owners accumulating over $100M in shares—a powerful vote of confidence now validated by improving fundamentals. The expanded Medicaid coverage in Texas and California opens new reimbursement pathways, potentially accelerating volume further. With the stock trading at 87x forward earnings and a $2B market cap, the profit inflection and reaffirmed guidance could shift sentiment from cash-burn concerns to a growth-at-scale narrative.
At the time of this announcement, WGS was trading at $60.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $32.21 to $170.87. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.